This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment. These defects were apparently reversible upon the discontinuation of tiagabine. Controlled clinical trials are indicated to determine if this finding is indicative of a class effect for all GABAergic antiepileptic drugs (AEDs), as already noted with vigabatrin, or if this case represents an incidental finding with tiagabine (41 references).
INTRODUCTION
Visual field defects (VFDs) are a significant adverse effect reported with the GABAergic antiepileptic drug (AED) vigabatrin 1, 2 . In small studies, the prevalence of VFDs has ranged from 40-83%, though most often these defects were asymptomatic [3] [4] [5] . VFDs have been reported to persist over time 6, 7 . Although most studies to date do not show significant reversibility of visual field loss, there are case reports that suggest VFDs may be reversible if the vigabatrin is withdrawn or lowered in dosage 8, 9 . Further, even if the VFDs are not reversible, other visual deficits (visual acuity / color vision / electroretinogram changes) may be reversible 10 .
Vigabatrin is primarily an irreversible GABAtransaminase inhibitor 11 . Vigabatrin also reduces GABA re-uptake activity 12 . As a result, the GABA levels in retinal cells are increased. It is thought that vigabatrin induced VFDs are secondary to GABA retinal toxicity 3, 13, 14 . If the defects are secondary to increased GABA, does that mean that all AEDs with similar mechanisms, increasing GABA levels, could cause VFDs? Both diazepam and progabide have been noted to cause VFDs, presumptively for the same reason 15, 16 . It has been suggested that patients on GABAergic AEDs (including vigabatrin, gabapentin, topiramate, and tiagabine) require periodic visual field evaluations or screening electroretinograms 3, 14, [17] [18] [19] . Since these newer GABAergic AEDs are also utilized in the treatment of bipolar disorders and pain syndromes, the magnitude of the at-risk population for VFDs is significantly greater than previously thought [20] [21] [22] [23] .
Tiagabine, in contrast to vigabatrin, causes increased extracellular GABA by functioning as a reuptake inhibitor only [24] [25] [26] . Compared to vigabatrin, the elevated GABA levels are lower and are not as persistent. To date, there have been only four abstracts published regarding the presence or absence of VFDs with tiagabine treatment [26] [27] [28] [29] .
This case represents the first patient treated with adjunctive tiagabine for bipolar affective disorder who developed VFDs that appear to have been reversible after discontinuation of tiagabine.
CASE REPORT Clinical 23
A 39-year-old white single male first presented in 1993 with a history of independent manic and depressive episodes consistent with DSM-IV diagnoses of bipolar affective disorder, alcohol abuse in remission, and co-morbid panic disorder with agoraphobia 30 . While being treated by a prior psychiatrist, he was nonresponsive to lithium, had side effects with nortriptyline, and was finally stabilized with total daily doses of carbamazepine 1000 mg, trazodone 200 mg, perphenazine 4 mg, and benztropine 2 mg. At time of initial assessment by this author in 1996, the patient had developed involuntary motor movements. With discontinuation of perphenazine and benztropine, these involuntary movements resolved. All baseline blood chemistries, including thyroid function tests, were within normal limits excluding elevated triglycerides (512 mg dL −1 ), cholesterol (217 mg dL −1 ) and GGT (417 IU L −1 ). MRI of the brain and EEG were both normal. The carbamazepine blood level was 9.9 ug ml −1 . With development of depressive features, trazodone was discontinued and paroxetine was titrated to 40 mg daily with resolution of these symptoms. After remaining stable for 1 year, the patient acutely developed significant manic features (excessive spending / pressured speech / road rage / marked irritability). In light of a history of fatty liver disease associated with prior alcohol abuse and persistently elevated GGTs (300s-400s), it was not felt prudent to titrate the carbamazepine further or to utilize valproate. Gabapentin was discontinued after the patient developed ataxia and confusion. The patient further regressed into a mixed bipolar state with predominantly psychotic depressive features. Use of clonazepam, lamotrigine and verapamil was excluded secondary to an early history of polysubstance abuse, a history of an allergic reaction to verapamil, and the patient's unwillingness to try lamotrigine secondary to potential risks 31, 32 . The rationale behind use of tiagabine, an AED without prior literature in the treatment of bipolar disorders, was explained to the patient in detail and he agreed to utilize tiagabine adjunctively (1/9/98). Within 2 weeks on total daily doses of tiagabine 4 mg, carbamazepine 1000 mg, and paroxetine 40 mg, the patient showed dramatic improvement (euthymic mood / no road rage / no hallucinations / minimal paranoia / normal interest level / significant improvement in sleep, appetite, and energy). Tiagabine was titrated to 12 mg daily to maximize improvement and within 1 month of initiation of tiagabine, the patient denied the presence of any psychiatric features.
The patient remained stable for >6 months on tiagabine 8 mg daily, carbamazepine 1000 mg daily, and paroxetine 40 mg daily after which an unsuccessful attempt was made to gradually switch to tiagabine monotherapy. Carbamazepine was reduced to 600 mg daily, paroxetine to 10 mg daily, and tiagabine was increased (based on re-emergence of symptoms) to 32 mg daily. Ultimately the patient was restabilized on tiagabine 12 mg daily, carbamazepine 600 mg daily, and paroxetine 20 mg daily. The patient was unable to be maintained on this regimen and a manic episode was precipitated by significant work/travel related sleep deprivation. Olanzapine was initiated at 7.5 mg daily with resolution of bipolar features. At the same time, his neurologist prescribed clonazepam 2 mg nightly for benign myoclonus. When VFDs were noted on visual field evaluation, tiagabine was discontinued (7/13/99) and low dose topiramate was initiated (7/29/99). During his 18-month exposure to tiagabine, his daily dose ranged from 4-32 mg with an average daily dose of 13.2 mg. The patient's topiramate has been gradually increased while maintaining affective stability. His present psychotropic regimen includes total daily doses of topiramate 125 mg, olanzapine 2.5 mg, carbamazepine 1000 mg, paroxetine 20 mg, and clonazepam 3 mg.
While under the care of this psychiatrist during the past 3+ years, the patient has been on the following other medications: amiloride, hydrochlorothiazide, lisinopril, atorvastatin, orlistat, melatonin, rofecoxib, ranitidine, beclomethasone dipropionate, albuterol, fenofibrate, tramadol, allopurinal, and loratadine. His non-psychiatric diagnoses include: hypertension, hyperlipidemia, gout, hiatal hernia, gastroesophageal reflux disorder, colitis, gallstones, fatty liver, sleep apnea, fibromyalgia, obesity, and benign myoclonus.
Visual findings
In light of the increasing literature supporting GABA based retinal toxicity associated with vigabatrin, and the presumptive potential for other GABAergic AEDs to have the same adverse side effects, automated static threshold perimetry (Allergan Humphrey 120-point full field screening test) was obtained at 13 months [OD = 7/120 absolute defects (AD); OS = 1/120 AD] and 18 months [OD = 9/120 AD; OS = 6/120 AD] at which time tiagabine was discontinued and topiramate was initiated. Post-discontinuation of tiagabine, Humphrey defects, absolute defects, and total points seen are summarized in Table 1 . Humphrey visual fields for the maximal VFDs are represented in Fig. 1 . Central 40-point screening tests performed on this patient in 1993 revealed 40/40 points seen OU. VEPs performed after the patient was on tiagabine for 11 months revealed an abnormal interocular difference of 7.42 milliseconds. Repeat VEPs were interpreted as normal with an interocular difference of 1.5 milliseconds. An MRI with and without gadolinium contrast was then performed and interpreted as normal.
Serial retinal and neuro-ophthalmologic evaluations revealed 'tiny' macular drusen OU, mild retinal vein tortuosity OU, unremarkable slit lamp examination OU, normal intraocular pressures OU, fundus examination with slightly anomalous optic disc OU without optic disc cup, and VFs normal to confrontation OU. During the neuro-ophthalmolgic evaluation performed on 3/30/00, Goldmann kinetic perimetry revealed normal inner and outer isopters OU, American Optical Hardy-Rand-Rittler (AOHRR) color plates were read correctly 20 out of 20 OU, no central metamorphosia was noted on Amsler grid OU though distortion was reported at the grid edges OU, stereoacuity resolved 50 seconds of arc, mild color desaturation was noted OS, and visual acuity was 20/20 OD and 20/15−1 OS with correction.
DISCUSSION
This case report suggests the development of VFDs associated with tiagabine adjunctive therapy that improved with discontinuation of the tiagabine. However, like most case studies, this report has numerous limitations and cannot be generalized. The most critical is that the patient did not have baseline visual fields or electroretinogram before receiving tiagabine and was not rechallenged with tiagabine to verify that the findings were causally related to that specific AED. However, as a clinical case there was insufficient data to support baseline evaluations and ethical considerations precluded rechallenging the patient with tiagabine. Confounding factors include the patient's multiple medical diagnoses and chronic medications. It is not possible to state that these played no role in the development of VFDs. Specifically, visual abnormalities have been reported with carbamazepine 33, 34 and long-term usage may have predisposed the patient to develop the VFDs noted in this patient. Further, drug-drug interactions may have played a significant role. For example, the patient was initially on low dosage tiagabine while receiving concomitantly the cytochrome P450 enzyme inducer carbamazepine; however, later in the treatment of this patient the tiagabine was increased to the maximum daily dose of 32 mg with a reduced daily dose of carbamazepine.
The initial worsening of VFDs OU during the first 2 months following discontinuation of tiagabine is consistent with a toxic process that reaches maximal effect before resolving. Although OS VFDs showed consistent improvement from that point over the course of treatment following tiagabine withdrawal, the OD VFDs initially improved but most recently showed gradual worsening. Is this post-tiagabine OD finding related to underlying pathology, to his other medications, or to a combination of both? This is an important finding; for excluding withdrawal of tiagabine and substitution with topiramate 15 months ago (7/29/99; average daily dose = 75.64 mg), his other medications have been stable over the course of the past 3+ years. It has been suggested that other GABAeric AEDs, including topiramate, may also be causative for VFDs 3, 16, 17, 19 . If the potential etiology is topiramate associated retinal toxicity, was it also predisposed by the prior AED tiagabine?
Although the Goldmann perimetry was noted to be normal (3/30/00), there are several possible explanations: (1) Goldmann and Humphrey perimetries are measured differently (the first is kinetic and the second is static); (2) the patient had already shown improvement in his VFDs when the Goldmann perimetry was performed; (3) it has been reported that in certain populations Humphrey perimetry detects visual field loss before Goldmann perimetry 35 .
The severity of VFDs in this case is relatively mild and the patient was asymptomatic. In this case, the VFDs noted by automated static threshold perimetry are best described as predominantly peripheral nasal constriction in nature. However, temporal sparing was present and one must wonder if the patient had remained on tiagabine would the VFDs have progressed to the more classic concentric VFDs noted with vigabatrin in severe cases 3, 6, 7, 36, 37 . Since tiagabine had been prescribed off-label for the treatment of bipolar disorders, and further agents (AEDs and atypical antipsychotics) are available, ethical considerations mandated the discontinuation of tiagabine in this case. Whether topiramate will be discontinued in light of the recent gradual worsening of the OD VFDs will depend on further visual field evaluations.
Vigabatrin VFDs have been associated with daily dose, total dose, and duration of treatment 5, 13, [38] [39] [40] . Whether this will be true with tiagabine or other GABAergic AEDs can only be determined with VF and electroretinogram evaluations in controlled clinical studies. The VFDs can be asymptomatic for years and VFs by confrontation or questionnaire cohort studies are not considered to be sufficient 40, 41 .
A summary of potential factors needing to be addressed in tiagabine VFDs, or those associated with other AEDs, include: total dose, maximal dose, rapidity of titration to maximum dosage, drug-drug interactions or cumulative effect upon retinal GABA levels secondary to other pharmaceuticals / genetic predisposition / selective vulnerability / other underlying pathology.
In light of the progression of VFDs over time, it is recommended that potential causative (GABAergic) AEDs have baseline VFs and electroretinograms with serial evaluations every 6-8 months. If VFDs are noted, the dosage of the AED should be decreased to determine if VFDs improve or stabilize. Since these VFDs are usually asymptomatic, continuation of the AED should be based on clinical necessity. If significant VFDs are noted when the AED is being used for off-label purposes, as in the treatment for bipolar disorders wherein other agents are available, ethical considerations mandate discontinuation of the AED. If the patient cannot be stabilized on alternative agents, then the AED should be re-initiated with detailed consent.
